Study to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female Subjects

Trial Identifier:	D8532C00002
Sponsor:	AstraZeneca
NCTID::	NCT05790304
Start Date:	February 2023
Primary Completion Date:	October 2023
Study Completion Date:	October 2023
Condition:	Liver, Pancreas & Gallbladder - Other

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service